Osimertinib improves progression-free survival in patients with EGFR mutated lung cancer
LUGANO-MADRID, 9 September, 2017 - Osimertinib improves progression-free survival by 54% compared to standard first line therapy in patients with EGFR mutated non-small-cell lung cancer...





